CAR-T cells have yielded unprecedented efficacy in B cell malignancies, most remarkably anti-CD19 CAR-T cells for B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate.
The ability to rewire our own immune system to fight cancer has certainly created huge expectations. After the success, more and more preclinical experiments and Phase I-III trials will be...
Portuguese (Brazil) 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Greek